Nycomed Gmbh

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.v.

Takeda Gmbh

Wilhelm Wurst

Beate Schmidt

Hans-Peter Kley

Guido Hanauer

Daniela Hauser

Andreas Keller

Klaus Eistetter

Gerhard Pohlmann

Wolfgang Koch

Horst Windt

Oliver Nolte

Jörg Kemkowski

Joerg Kemkowski

Dirk Bredenbroeker

Renate Engelstaetter

Thomas Bethke

Dirk Bredenbröker

Dietrich Hafner

Frank Rathgeb

Christoph Karl

Peter Schaffer

The invention relates to a devicefor dosing and dry nebulization of nebulizable materialchosen from the group comprising anti-infective agents and immunomodulators, comprising a nebulization channel, which has a first attachment piece and a second attachment piece, and a source of compressed carrier gas connected to the first attachment piece via a valvefor the purpose of sending a carrier gas pressure pulse into the nebulization channel. The device is characterized in that between the first attachment piece and second attachment piece, and above the nebulization channel, a reservoiropen only towards the nebulization channel, which contains the nebulizable material, is connected to the nebulization channel such that it is gas-tight with respect to the environment, and that, when the valve is closed, a pressure compensation takes place in the nebulization channel and in the reservoir. The invention also relates to a method for dosing and dry nebulization of such a nebulizable material by means of such a device.

Device for dosing and dry nebulization

The application relates to specific combinations of Roflumilast and/or Roflumilast N-Oxide and a PPAR-agonist, as well as their use in the treatment of diabetes mellitus type 2.

Roflumilast for the treatment of diabetes mellitus type 2

The invention relates to new method of treatment of respiratory diseases, in particular the treatment of asthmatic children.

Use of ciclesonide for the treatment of respiratory diseases

The invention relates to the use of Roflumilast and/or Roflumilast N-Oxide for the treatment of diabetes mellitus and accompanying disorders thereof. The invention additionally relates to combinations of Roflumilast and/or Roflumilast N-Oxide with other active agents for the treatment of diabetes mellitus.

Roflumilast for the treatment of diabetes mellitus

Growing community of inventors

Constance, Germany

Wilhelm Wurst